Top Cannabis Investment News, Member Posts, Cannabis Investment Daily Indices and more!

1yr ago Cannabis greenmarketreport Views: 354

-

Seelos Therapeutics Inc. (Nasdaq: SEEL) announced the completion of enrollment of its registrational Phase II/III trial studying the investigational treatment SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) on the HEALEY ALS Platform Trial.

Trehalose is a naturally occurring disaccharide that is widely distributed throughout the biological world and is found in plants, algae, fungi, yeasts, bacteria, insects, and other invertebrates.

“The full enrollment of this study is a significant milestone for Seelos. We look forward to releasing the topline data later this year and initiating the expanded access program later this quarter,” said Raj Mehra Ph.D., chairman and CEO of Seelos.

Seelos said that its Phase II/III trial (NCT05136885) enrolled 160 participants with either familial or sporadic ALS for a double-blind placebo-controlled trial. Participants were randomized 3:1 (drug:placebo), with the primary endpoint measuring the change from baseline on the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score at 24 weeks. Secondary endpoints include change from baseline in slow vital capacity, muscle strength, quality of life measurements as well as additional signs of disease progression.

Seelos’ planned expanded access program (EAP) is fully funded by a grant from the National Institute of Neurological Disorders and Stroke under the ACT for ALS. Under this EAP, Seelos plans to enroll 70 patients in a 24-week, open-label study to evaluate SLS-005 in persons with ALS who do not qualify for other ongoing clinical trials, thus offering these patients an experimental treatment that they may not otherwise have access to.

Ketamine Study

Seelos is also known for its ketamine studies, and last week the company reported that it had dosed the first patients in an ethnobridging study in healthy adult Japanese and non-Asian subjects to compare the safety and pharmacokinetic profiles of SLS-002 (intranasal racemic ketamine).

Seelos consulted and received endorsement from the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan and from the U.S. Food and Drug Administration (FDA) to conduct this Phase I ethnobridging study.

“This ethnobridging study is an important first step as we begin evaluating the potential for SLS-002 in patients globally,” Mehra said. “Our market research suggests a high unmet global need for a therapy with both antidepressant and antisuicidal effects.”

Study SLS-002-103 will measure elements such as dosage and administration, sample size, inclusion and exclusion criteria, endpoints, and blood sampling. Seelos expects that data from this study will help inform the inclusion of Japanese subjects in the design of a future global trial in patients with major depressive disorder (MDD) at imminent risk of suicide.

Seelos Makes Progress on ALS Study Trial on Green Market Report.


Today's Cannabis Investment Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.